CoQ10 (coenzyme Q10) is one of the most recognisable ingredients on a supplement label, and one of the most misunderstood. Brands abroad ask for it by the “reduced” or “ubiquinol” name because marketing around absorption is loud, and they ask for a Japan-made version because Japan has decades of manufacturing experience with it.
This guide is for brand owners planning a Japan-made CoQ10 product. It covers what the absorption and exercise-fatigue research actually shows, why CoQ10 is almost always sold in a softgel, Japan’s regulatory history with the ingredient, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a CoQ10 product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Ubiquinol (the reduced form) sometimes shows better absorption than ubiquinone (the oxidised form), but the advantage is inconsistent between studies and populations, and exercise-fatigue trials in healthy adults report small, mixed effects.
| Study | Design / what was analysed | Reported result |
|---|---|---|
| Randomised, double-blind, crossover trial, Clinical Pharmacology in Drug Development 2026 (PMID 41789786, PMC12965043) | 12 healthy adults aged 45–65; single-dose comparison of a novel cocrystal ubiquinol formulation against a standard ubiquinone formulation | The ubiquinol formulation showed substantially higher bioavailability (AUC ratio around 2–3× versus the ubiquinone reference) |
| Randomised, three-period crossover trial, Nutrients 2020 (PMID 32188111) | 21 healthy older adults aged 65–74; single 100 mg doses of a water-soluble CoQ10 syrup, ubiquinol capsules and ubiquinone capsules compared head-to-head | The water-soluble formulation was significantly more bioavailable than ubiquinone (2.4-fold, p = 0.002); ubiquinol showed only a non-significant 1.7-fold increase over ubiquinone |
| Systematic review and meta-analysis, British Journal of Nutrition 2025 (PMID 41457257) | 24 studies to November 2025 on CoQ10, exercise performance, subjective fatigue and blood CoQ10 in healthy adults | Supplementation reliably raised blood CoQ10, but effects on exercise performance were small and inconsistent; chronic dosing showed a small benefit that was no longer stable once outlying studies were excluded, and acute dosing showed no benefit |
| Randomised, double-blind, crossover trial, Journal of Strength and Conditioning Research 2010 (PMID 19644406) | 15 healthy, sedentary men; 100 mg/day CoQ10 or placebo for 8 weeks, then five repeated Wingate sprint tests | Peak power declined with both CoQ10 and placebo across repeated sprints; mean power was higher with CoQ10 only in the final (fifth) sprint, with no consistent effect across the other tests |
Four points worth keeping in view:
- The ubiquinol-absorption advantage is not settled. The 2026 crossover trial found a large advantage for a novel cocrystal ubiquinol formulation, but that is a specific delivery technology, not plain ubiquinol. The 2020 trial in older adults, comparing ordinary ubiquinol and ubiquinone capsules directly, found the difference did not reach statistical significance. Both trials were funded at least partly by companies — the 2026 trial by the cocrystal ingredient’s manufacturer, the 2020 trial jointly by a national research agency and a company.
- Age and formulation both move the result more than “reduced versus oxidised” alone. Trials group products by carrier, particle size and dose, not only by chemical form, and results are population-specific — what holds in adults over 65 does not automatically apply to younger, healthy adults.
- Fatigue and exercise-performance results in healthy people are small and mixed. The largest recent review found the effect became unstable once a few influential studies were removed, and an earlier crossover trial found a benefit in only one of five repeated sprint tests.
- None of this is heart-health evidence. CoQ10 research in heart-failure patients is a separate, medical body of literature (see below); it does not apply to a food product sold to healthy consumers.
Checked against the published abstracts on 12 October 2026.
What Japanese products say
CoQ10 (ubidecarenone) began in Japan as a prescription medicine, and only later became available as a food ingredient — a history that shapes how it must be worded today.
CoQ10 entered Japanese clinical use as a prescription drug in the 1970s, for congestive heart failure, and later became available over the counter as a pharmaceutical as well. In 2001, Japan’s Ministry of Health, Labour and Welfare permitted CoQ10 to also be treated as a food ingredient, on condition that no medical or pharmacological effect is claimed for it — the same condition that applies to any ingredient moved onto that food/drug borderline list. We were not able to verify an official specific milligram intake limit from a primary MHLW source, so this guide does not state one; ask your factory for the current guidance before finalising a dose.
Two consequences for a brand abroad:
- The prescription history is real, but it is not your product’s story. CoQ10’s medical use for heart failure in Japan belongs to the pharmaceutical form under medical supervision. A food-form CoQ10 product cannot borrow that history as a claim.
- “Permitted as a food” is a Japanese food-law status, not a global one. Confirm CoQ10’s status as a food or supplement ingredient in your own market before you commit to a formula.
💬 Need a regulatory summary that separates Japan’s food-status history from its medical history? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe CoQ10 by what has been studied and in which population, never by the heart condition its medical form is used for.
| Safer wording | Wording to avoid |
|---|---|
| ”Contains CoQ10 (ubiquinone or ubiquinol), [amount] per serving" | "Supports heart health”, “for blood pressure”, any cardiovascular claim |
| ”Studied for exercise-related fatigue in healthy adults, with mixed results" | "Boosts energy” or “beats fatigue” without qualification |
| ”Reduced form (ubiquinol), included for its absorption profile" | "Proven better absorbed” stated as settled fact |
How CoQ10 is formulated
CoQ10 is oil-soluble and barely dissolves in water, so it is almost always formulated as a soft (softgel) capsule carrying it in an oil base — a formulation fact, not a claim.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Soft (softgel) capsule with an oil carrier | The standard format; suits CoQ10’s oil solubility directly | Shell material (gelatin or plant-based) and dietary suitability |
| Hard capsule with a pre-solubilised powder or granule | Avoids gelatin softgel shells if the brand needs a vegan capsule | Needs a solubilised or micronised raw material, not plain crystalline powder |
| Combined with another oil-soluble ingredient (e.g. astaxanthin, vitamin E) | Shares the oil carrier and the softgel line | Stability and colour of the combined oil fill |
Decisions that shape the specification:
- Form. Ubiquinone (oxidised) or ubiquinol (reduced). Ubiquinol typically costs more; whether that is worthwhile depends on your target population and how you plan to word the claim.
- Amount per serving. Match the amount to any study you intend to cite, and check your market’s own rules on daily intake.
- Carrier oil and solubilisation. Plain crystalline CoQ10 absorbs poorly; ask the supplier how the material is solubilised or particle-reduced, and for its own bioavailability data.
- Companion ingredients. CoQ10 is often paired with other oil-soluble actives. Each one needs its own check against Japanese food law.
- Packaging and stability. CoQ10 is sensitive to light and oxidation; opaque blister packs or bottles are standard.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
CoQ10 itself is permitted as a food ingredient in Japan, subject to the no-medical-claim condition above. The risk in an “energy” or “sport” formula usually sits in a companion ingredient, not in CoQ10 itself — some botanicals and extracts sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and our GABA and lactic acid bacteria guides for two more examples of reading the evidence honestly before you commit to a formula.
Before you ask for a quotation
A factory can quote accurately once the form, the amount, the carrier and the packaging are fixed.
- CoQ10 form (ubiquinone or ubiquinol) and amount per serving
- Carrier oil and solubilisation technology
- Capsule shell material (gelatin or plant-based)
- Companion ingredients and their amounts
- Packaging (light and oxidation protection)
- Countries you will sell in, and CoQ10’s status there
💬 Ready to design a Japan-made CoQ10 product? Send us the concept — form, amount, carrier and the countries you will sell in.
Frequently asked questions
1. Is ubiquinol really better absorbed than ubiquinone?
Sometimes, but not reliably. A 2026 crossover trial found a large advantage for a specific ubiquinol cocrystal formulation, while a 2020 trial comparing ordinary ubiquinol and ubiquinone capsules in older adults found the difference was not statistically significant. Absorption depends heavily on the specific formulation and the population studied, not on the chemical form alone.
2. Why is CoQ10 almost always a softgel capsule?
Because it is oil-soluble and barely dissolves in water. A softgel carries it in an oil base, which is the most direct way to formulate it. Other formats exist, but they need a pre-solubilised or micronised raw material to absorb reasonably well.
3. Does CoQ10 improve exercise performance or reduce fatigue in healthy people?
The evidence is small and mixed. A 2025 systematic review of 24 studies found blood CoQ10 levels rose reliably with supplementation, but performance effects were small and became unstable once a few influential studies were excluded. An earlier crossover trial in sedentary men found a benefit in only one of five repeated sprint tests.
4. Was CoQ10 originally a medicine in Japan?
Yes. CoQ10 entered Japanese clinical use as a prescription drug in the 1970s for congestive heart failure. In 2001, Japan’s health ministry permitted it to also be used in foods, provided no medical effect is claimed. That medical history belongs to the pharmaceutical form and is not a claim for a food product.
5. Can I say my CoQ10 product supports heart health?
No. CoQ10’s use in heart failure is medical territory in Japan and elsewhere, and it is off-limits for a food supplement’s wording. Describe the product by what has actually been studied in healthy people — absorption and exercise-related fatigue — with the honest, mixed results those studies show.
Sources: “A Randomized, Double-Blind, Two-Treatment, Two-Period, Crossover Study Investigating the Systemic Bioavailability of a Novel Cocrystal Ubiquinol Formulation Compared with a Ubiquinone Formulation in Healthy Adults”, Clinical Pharmacology in Drug Development 2026 (PMID 41789786, PMC12965043); “Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals”, Nutrients 2020 (PMID 32188111); “Coenzyme Q10 supplementation increases blood concentrations but shows limited and inconsistent effects on exercise performance: a systematic review and meta-analysis”, British Journal of Nutrition 2025 (PMID 41457257); “The Effects of Coenzyme Q10 Supplementation on Performance During Repeated Bouts of Supramaximal Exercise in Sedentary Men”, Journal of Strength and Conditioning Research 2010 (PMID 19644406); Kettawan A, et al. “The Quality Control Assessment of Commercially Available Coenzyme Q10-Containing Dietary and Health Supplements in Japan”, Journal of Clinical Biochemistry and Nutrition 2007;41(2):124–131 (PMID 18193106), for CoQ10’s regulatory history in Japan. Checked on 12 October 2026.